arrow
B

Bhargava Kandala

Merck & Co. Inc
H指数:7
被引数:199

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial (vol 42, pg 145, 2024)

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验 (第42卷,145页,2024)

2024-05-200
OAAI
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

CXCR2拮抗剂navarixin联合pembrolizumab治疗晚期实体瘤: 一项2期随机试验

2024-02-0718
OAAI
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? (vol 23, 48, 2021)
2021-11-220
OA
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
2021-03-2515
OA